Lifastuzumab vedotin: Difference between revisions
CSV import |
No edit summary |
||
| Line 21: | Line 21: | ||
{{stub}} | {{stub}} | ||
<gallery> | <gallery> | ||
File:Vedotin_ADCs.svg|Vedotin ADCs | File:Vedotin_ADCs.svg|Vedotin ADCs | ||
</gallery> | </gallery> | ||
Latest revision as of 00:39, 17 March 2025
Lifastuzumab vedotin is an antibody-drug conjugate designed to treat cancer. It is composed of the monoclonal antibody lifastuzumab linked to the cytotoxic agent monomethyl auristatin E (MMAE). The antibody portion of the drug binds to HER3, a protein that is overexpressed in certain types of cancer, and delivers the cytotoxic agent directly to the cancer cells.
Mechanism of action[edit]
Lifastuzumab vedotin works by targeting the HER3 protein on the surface of cancer cells. The lifastuzumab portion of the drug binds to HER3, and the drug is then internalized by the cell. Once inside the cell, the MMAE is released and interferes with cell division, leading to cell death.
Clinical trials[edit]
Lifastuzumab vedotin has been tested in clinical trials for the treatment of various types of cancer, including breast cancer, lung cancer, and gastric cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.
Side effects[edit]
The most common side effects of lifastuzumab vedotin include fatigue, nausea, and decreased appetite. More serious side effects can include neutropenia, peripheral neuropathy, and pulmonary toxicity.
